MYD88 and ovarian carcinoma: In EOC, we and others have shown that CD44+/MyD88+ epithelial ovarian cancer stem cells (EOC stem cells) possess tumor-initiating properties and exhibit diverse resistance to a wide-range of chemotherapy agents including, but not limited to, platinums and taxanes [20-26].